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Two therapeutic modalities, zidovudine (targeting retroviral replication) and cyclosporin A
(targeting immunopathologic consequences of retroviral expression) were evaluated in a murine
model of AIDS. In previous studies, cyclosporin A treatment (40 or 60 rug/kg/day) before and
after infection with LP-BM5 murine leukemia viruses protected against the development of
immunodeficiency disease. The present study extends these findings. First, a low dose of cyclo-
sporin A (20 rug/kg/day) was ineffective, and treatment initiated 5 days after infection did not
protect against virus-induced lymphoproliferation and hypergammaglobulinemia. Second, zido-
vudine added to drinking water (0.1 mg initiated 5 days after infection and continued for 8 weeks)
was more effective than 0.2 mg/ml, given day 5-12 after infection. This treatment reduced
lymph node size, disease severity as determined histologically, retrovirus-induced gp70 expres-
sion, and IgE (but not IgM and IgG) levels. Third, combined treatment had an additive, protec-
tive effect on lymphocyte proliferative capacity. This successful dual therapeutic strategy in a
mouse model has potential applicability for similar approaches in treating human immunodefi-
ciency virus infection.
The LP-BM5 murine leukemia viruses (MuLV) induce an
immunodeficiency disease in susceptible murine strains [1-
6]. The disorder has a natural history in many ways compara-
ble to human immunodeficiency virus (HIV-l )-induced
AIDS in humans and has therefore been termed murine
AIDS (MAIDS) [3]. Dysfunction of CD4+ T cells is a key
feature in both conditions and precedes a numerical reduc-
tion of this T cell subset even though the LP-BM5 viruses
have no selective tropism for CD4+ T cells [7].
Previous studies of mice with MAIDS demonstrated that
interactions between CD4+ T cells and B cells are central to
the pathogenesis of this syndrome; infected mice depleted in
vivo of CD4+ T cells had phenotypically and functionally
normal B cells [8], while infected mice depleted of mature B
cells had phenotypically and functionally normal CD4+ and
CD8+ T cells [9]. Indirect evidence suggests that B cell-de-
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pendent T cell activation through a mechanism involving a
retrovirus-associated superantigen is crucial to the develop-
ment of the disease [10]. Furthermore, inappropriate regula-
tion oflymphokine expression, including genes encoding in-
terferon (IFN)-a, -{3, and --y [II], interleukin (IL)-1 [12], -2
[7, 13], -4, -5, -6, and -10 [13], and tumor necrosis factor
[12], may be of importance.
We have analyzed the therapeutic effect of cyclosporin A,
which interferes with crucial steps in T cell activation [14].
Treatment with cyclosporin A (40 and 60/mg/kg/day) be-
fore and after infection with LP-BM5 MuLV significantly
inhibited the development of immunologic and histopatho-
logic changes characteristic of MAIDS [15]. This study ex-
tends our analysis by using cyclosporin A at lower doses ei-
ther alone or combined with zidovudine, an inhibitor of
retroviral reverse transcriptase [16].
Materials and Methods
Miceand viruses. Inbred female C57BL/6 (B6; H_2b ; suscep-
tible to LP-BM5-induced disease) mice were obtained from
IFFA Credo (I'Arbresle, France). Mice were injected at the age
of 4 weeks intraperitoneally with 0.1 mL of LP-BM5 MuLV
stock containing a replication-defective component as described
[2, 5,6] and ---10 ffu/rnl, MCF (mink cell focus-inducing) virus
and 103.8-105 pfu/ml, ectropic MuLV.
Drug treatments. Cyclosporin A was a gift of J.-F. Borel
(Sandoz, Basel, Switzerland). The powder was dissolved in alco-
hol and tween 80, diluted with PBS, and injected daily intraperi-
toneally. Either 20 or 40 rug/kg/day was begun I day before
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Figure 1. Experimental protocol. B6 mice were infected with
LP-BM5 murine leukemia virus at 4 weeks old. Zidovudine (AZT)
was added to drinking water beginning 5 days after infection, either
at 0.2 mg/mL for I week (ET, early treatment) or at 0.1 mg/mL
until end of experiment at 8 weeks (CT, continuous treatment).
Cyclosporin A (CSA) was given at 20 or 40 rug/kg/day intraperito-
neally: treatment was begun I day before infection or 5 days after
(.).
infection or 5 days after infection until the end of the experi-
ment 8 weeks later.
Zidovudine was supplied by Wellcome Research Laboratories
(Beckenham, UK) and administered orally in the drinking water
at a concentration of0.2 mg/mL days 5-12 after infection (early
treatment) or at 0.1 mg/rnl. from day 5 until the end of the
experiment (continuous treatment). The doses used did not in-
duce toxicity, and mouse weight, hematocrit, and histology of
major organs remained unaffected.
Treatment regimens are shown in figure I. Two independent
sets of experiments were done, and representative results from
one set are reported.
Histopathology. Samples of all major organs were obtained
at autopsy, and histologic sections were stained with hematoxy-
lin-eosin. The histopathologic staging was done by an immuno-
pathologist blinded for the experimental protocol according to
criteria previously described [3]. Briefly, splenic histology is de-
fined as reactive (R) by hyperplasia of periarterial lymphoid
sheaths and follicles due to accumulation of immunoblasts and
plasmocytoid cells as well as plasma cells without distortion of
their round shape. Stage I is distinguished by an eccentric hyper-
plasia of the periarterial sheaths with hourglass shapes. The
mantle zone is still intact and there is no compression of the red
pulp. In stage II, there is extensive enlargement of periarterial
sheaths, loss of the mantle zone, and compression of the red
pulp. Lymphoid masses are still separated by stretches of red
pulp. In stage III, nodular confluent masses of lymphoid tissue
are associated with obliteration of the red pulp.
Serology. Serum immunoglobulin levels were determined
by ELISA with immunoglobulin class- and subclass-specific re-
agents and standards as detailed elsewhere [17, 18]. The determi-
nation of serum gp70 levels has been described [19].
Proliferative responses. Proliferative responses to mitogens
were induced in cultures ofspleen cells (2 X lOS/well) in 0.2 mL
of Dulbecco's modified Eagle medium (DMEM) supplemented
AZl
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assay
with 10%fetal calfserum, 2'-mercaptoethanol, and antibiotics in
96-well microtiter plates (Costar, Cambridge, MA). Concanava-
lin A (2 JIg/mL; Pharmacia, Uppsala, Sweden) and lipopolysac-
charide (20 JIg/mL; Escherichia coli 055:B5; Difco, Detroit)
were added at the beginning and cultures were pulsed overnight
with [3H]thymidine before harvesting after 48 h.
Statistical analysis. The Wilcoxon signed rank test was
used.
Results
Effect ofzidovudine and cyclosporin A treatment on develop-
ment of lymphadenopathy and histopathologic changes.
Infection with the LP-BM5 viruses is associated with subse-
quent lymphoproliferation due to polyclonal T and B cell
expansion. Disease progression is paralleled by typical
changes in splenic histomorphology.
Table I summarizes the effect of cyclosporin A and zido-
vudine on lymphoid organ size and on histopathology. The
higher dose ofcyclosporin A (40 mg/kg/day) was effective in
reducing lymph node size, but only when treatment was initi-
ated before infection (P < .05). Treatment with zidovudine
was more efficacious when given continuously than when
given during days 5-12 only. Combining zidovudine and
cyclosporin A resulted in a further significant reduction of
lymph node size compared with treatment with either contin-
uous zidovudine (P < .05) or cyclosporin A (P < .05) alone.
Disease severity, quantitated by morphologic criteria, was
attenuated by cyclosporin A treatment initiated before and
continued after infection. Infected mice treated with cyclo-
sporin A at 40 mg/kg/day showed mostly reactive changes
irrespective of whether zidovudine was coadministered. Zi-
dovudine alone (continuous treatment), however, did attenu-
ate histologic disease severity. Cyclosporin A initiated 5 days
after infection reduced disease severity to a lesser but statisti-
cally significant degree (P < .05).
Effect ofzidovudine and cyclosporin A treatment on develop-
ment of hypergammaglobulinemia. LP-BM5 infection in-
duces rapid and sustained polyclonal B cell activation result-
ing in hypergammaglobulinemia [20, 21]. Treatment of
infected mice with cyclosporin A resulted in a dose-depen-
dent reduction of all immunoglobulin isotypes tested when
treatment was initiated before infection (table I). No signifi-
cant effect was observed when the drug was started 5 days
after infection. Zidovudine treatment did not significantly
affect hypergammaglobulinemia of the IgM and IgG isotypc
observed in infected mice, nor did it add to the effect of
cyclosporin A when the drugs were used together. However.
IgE levels were reduced by continuous zidovudine treat-
ment compared with those seen in infected untreated mice
(P < .05).
Effect of zidovudine and cyclosporin A treatment on serum
gp70 expression. Serum gp70 levels can be used as a means
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Table 1. Effect ofzidovudine and cyclosporin A treatment on development oflymphadenopathy, histopathologic alterations, and hyper-
gammaglobulinemia.
Serum immunoglobulin levels
Cervical lymph Histopathologic
Treatment regimen, infection node weight, mg stage IgM,pg/mL IgO, mg/ml, IgE, ng/mL
None
Uninfected 17 (6) NO 296 (224) 7.9 (2.6) <20
Infected 224 (82) II (I-Ill) 1556 (297) 32.9 (3.5) 572 (475)
Cyclosporin A before infection
20 mg/kg/day
Uninfected 12 (4) NO 260 (187) 8.6(1.9) NO
Infected 220 (101) NO 1295 (612) 35.7(3.1) NO
40 rug/kg/day
Uninfected 10 (0) NO 464 (193) 9.6 (2.3) 43 (17)
Infected 90 (14) R (N-R) 452 (139) 19.9 (3.8) 136(145)
Cyclosporin A after infection
20 rug/kg/day, infected 335 (107) ND 1224(593) 31.3 (3.6) NO
40 rug/kg/day, infected 494 (242) I (R-II) 816(230) 27.3(5.1) 395 (559)
Zidovudine, early treatment
Uninfected 10 (0) NO 147 (46) 7.1(1.5) NO
Infected 213(106) II (I-II) 1302 (252) 28.6 (3.2) 875 (322)
Zidovudine, continuous treatment
Uninfected 10 (0) NO 103 (25) 5.4 (1.7) NO
Infected 130 (49) I (R-II) 1117 (304) 30.1 (3.9) 161 (81)
Cyclosporin A, 40 mg/kg/day, plus zidovudine
Early treatment, infected 67 (28) R (R) 303 (63) 15.2 (2.8) 21 (3)
Continuous treatment, infected 66 (34) R (N-R) 856(312) 21.6 (6.6) 94 (81)
NOTE. Intraperitoneal treatment with cyclosporin A (groups of6 B6 mice) was begun at age 4 weeks, I day before or 5 days after infection with LP-BM5
murine leukemia viruses,and continued for 8 weeks.Zidovudine was added to drinking water 5-12 days after infection at 0.2 mg/mL (early treatment) or from
day 5 after infection for 8 weeks at 0.1 mg/ml, (continuous treatment). Histopathologic staging, given as median (range): N, normal; R, reactive; l-Hl, discrete
and progressive stages of disease severity. Other data are mean (SO). NO = not done.
to quantify retroviral expression, as shown previously for LP-
BM5 MuLV [15]. Figure 2 shows increased gp70 levels for
infected compared with uninfected mice. These increases
were not affected by treatment with cyclosporin A alone.
However, chronic administration of zidovudine lowered
gp70 expression. When infected mice were compared, differ-
ences between those untreated and continuously zidovudine
treated were significant (P < .03), as were differences be-
tween mice treated with cyclosporin A (40 rug/kg/day) and
with the combination of cyclosporin A (40 mg/kg/day) and
zidovudine (P < .03 for early or continuous treatment). In
other words, zidovudine (early treatment) combined with cy-
closporin A was more effective than zidovudine (early treat-
ment) alone or cyclosporin A alone.
Effect of zidovudine and cyclosporin A treatment on mito-
gen-induced proliftrative responses. Eight weeks after infec-
tion, spleen cells were assessed for their capacity to respond
to stimulation with the mitogens concanavalin A and lipo-
polysaccharide (table 2). Proliferative responses were almost
totally abrogated in spleen cells from infected untreated
mice compared with those from uninfected control mice,
changes characteristic of MAIDS [1, 7, 20]. Treatment with
cyclosporin A or zidovudine alone did not beneficially influ-
ence unresponsiveness of splenocytes, as previously re-
ported, reflecting a more advanced stage of disease progres-
sion in the present study [IS]. Combining both drugs,
however, led to a significant increase in proliferative re-
sponses irrespective ofwhether zidovudine was given as early
or continuous treatment (P < .05).
Discussion
Therapeutic strategies are generally designed to interfere
with crucial steps in the pathogenetic sequence of a disease
process. According to our working hypothesis, LP-BM5
MuLV-induced immunodeficiency can be viewed as a retro-
virus-triggered superantigen-driven polyclonal stimulation
of the immune system followed by exhaustion of immune
function [10]. In spite of major differences in viral tropism
and replication between MAIDS and AIDS, recent indirect
evidence underlines a possible pathogenic role for a retrovi-
rus-encoded superantigen in AIDS [22]. Others consider the
disease a primary neoplasia with an acquired immunodefi-
ciency syndrome as a paraneoplastic syndrome [23].
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Figure 2. Effect of treatment with cyclosporine A (CSA) and
zidovudine (AZT) on serum gp70 levels in LP-BM5-infected and
uninfected B6 mice. gp 70 levels ofsera obtained after 8 weeks from
6 mice per group were determined by ELISA; results are means ±
SDs. Treatment regimens are explained in legend to figure I.
Two therapeutic modalities, zidovudine (targeted at retro-
viral replication) and cyclosporin A (aimed at the immuno-
pathologic consequences of virus expression), were evalu-
ated in this study.
The effect of cyclosporin A on MAIDS is dose dependent.
A dose of 40 or 60 rug/kg/day is necessary to suppress the
rate at which disease develops; 20 rug/kg/day is not effective.
Results obtained in other studies using cyclosporin A in vivo
suggest that doses in the range of 15-30 mg/kg abrogate self-
Ia-restricted T helper function and that higher doses are re-
quired to suppress other T cell functions [24]. Treatment
with cyclosporin A has to be initiated very early to influence
the disease process; administration before viral infection pro-
tects mice against MAIDS, whereas a delay of 5 days renders
the disease resistant to the action of cyclosporin A used at 40
rng/kg/day. This was not because of interference with helper
retrovirus expression, since cyclosporin A-treated infected
mice had similar levels of serum gp70, as shown here, and
LP-BM5 ecotropic MuLV, as reported previously [15].
Although the molecular mechanism of cyclosporin A ac-
tion is still incompletely understood, its main mode ofaction
both in vitro and in vivo is interference with lymphokine
expression during T cell activation [14,24-26]. Recent stud-
ies of cytokine production in MAIDS suggest at least two
distinct phases of the disorder [13]. At I week after infection
there is a burst ofspontaneous proliferation and moderate- to
high-level expression of IL-2, -4, -5, and -10 and IFN-')' by
spleen cells, a pattern consistent with activation of ThO or a
NOTE. Treatment regimens are explained in footnote to table I. Data
are mean (SO) ~cpm X I000. ~cpm = cpm of thymidine incorporation of
mitogen-containing cultures - cpm of unstimulated cultures.
17 (3)
14 (7)
57 (29)
5 (4)
97 (23)
4 (2)
106 (22)
2 (2)
118 (27)
3 (2)
78 (15)
9 (3)
93 (II)
6 (2)
95 (24)
9 (2)
32 (14)
18 (21)
103 (19)
6 (4)
Lipopolysaccharide Concanavalin A
Table 2. Effect of zidovudine and cyclosporin A treatment on
mitogen-induced proliferative responses of spleen cells in murine
AIDS.
mixture of Th I and Th2 helper cells. However, at 2 weeks
after infection and thereafter, cytokine expression by spleen
was seen only after stimulation ofcells with concanavalin A,
and the pattern of expression was that ofTh2 cells only (IL-
4, IL-l 0). It is most likely the very early process of virus-de-
pendent T cell activation and cytokine expression that is cru-
cially interfered with by treatment with cyclosporin A at the
time of infection. Treatment beginning at later times might
be expected to be less effective, as Th2 cells are 10-fold
more resistant to the effects of cyclosporin A than are Th I
cells [27].
Hypergammaglobulinemia encompassing IgM, IgG (all
subclasses), and IgE reflects activation ofboth Th I and Th2.
The effect of cyclosporin A on hypergammaglobulinemia
was not biased towards a particular isotype, suggesting imped-
iment of both T helper pathways. This is in accord with in
vitro and in vivo studies in which cyclosporin A affected
expression oflymphokines belonging to both Th subsets, al-
though, as noted above, Th2 cells are more resistant to the
effects of cyclosporin A than are Th I cells [24, 26, 27].
Zidovudine has previously been used alone or combined
with other nucleoside inhibitors in the LP-BM5 mouse
model [28-31]. Several groups reported an effect of oral zi-
dovudine on the development of immune abnormalities; one
used a higher dose (I mg/mL) [29], one initiated the treat-
ment on the day of viral infection and used a lower dose (30
mg/kg/day) [30], and another began 24 h after infection and
used low doses (0.25 and 0.1 mg/mL) [28]. The dose used
here, 0.1 mg/mL corresponds to --25 mg/kg/day and was
not toxic, even when given for prolonged periods of time, as
Treatment regimen, infection
None
Uninfected
Infected
Cyclosporin A, 40 mg/kg/day
Uninfected
Infected
Zidovudine, early treatment
Uninfected
Infected
Zidovudine. continuous treatment
Uninfected
Infected
Cyclosporin A plus zidovudine
Early treatment, infected
Continuous treatment, infected
BMS CSA AZT
124 6 8 10
serum gp 70 (~glml)
2
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in these or other previously reported studies [28]. Low-dose
zidovudine treatment of an established HIV infection is the
clinical setting that we tried to mimic in our study design. We
found zidovudine given continuously effectively reduced
gp70 expression and, in addition, inhibited the development
oflymphadenopathy and attenuated histopathologic signs of
disease progression. No significant effect on hypergamma-
globulinemia, except IgE, was observed. There was an addi-
tive effect when both zidovudine and cyclosporin A were
used in preserving mitogen responsiveness of splenic lym-
phocytes.
Further studies are required before cyclosporin A can be
considered as a candidate drug for the treatment of HIV-in-
fected humans. A preliminary study of 11 patients with ad-
vanced HIV disease treated with a short course of cyclo-
sporin A failed to show a beneficial effect on CD4 cell counts
[32]. A recent report of 88 HIV-infected patients with solid
organ transplants, most ofwhom were treated with immuno-
suppressants including cyclosporin A, found no effect, either
beneficial or harmful, of cyclosporin A on the course of in-
fection with HIV [33].
This study presents a successful attempt to develop a dual
therapeutic strategy combining antiviral (zidovudine) and
immunomodulatory (cyclosporin A) drugs in a mouse model
of AIDS that will potentially form the basis for designing
similar approaches for humans infected with HIV.
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